News on this topic
The treatment landscape for HER2-mutated advanced #NSCLC continues to evolve.
Stay up to date with expert perspectives on the latest data and what it could ... Show more
Ongoing Perspectives in HER2-Mutated Advanced NSCLC: An Expert Viewpoint on the Latest Data
Ongoing Perspectives in HER2-Mutated Advanced NSCLC: An Expert Viewpoint on the Latest Data
Similar to This
Previous

GSK won U.S. approval for its second lung cancer drug from the Nuvalent deal: The FDA granted accelerated approval to neladalkib, sold as Nelkarmi ...
qz.com/gsk-neladalkib-nelkarmi-fda-approval-nuvalent-111726
China's Biotech Powerhouse 25: New Chinese biotechnology index for pharma execs and life science investors, China’s Biotech Powerhouse 25 ...
statnews.com/china-biotech-index-powerhouse-25/

Pharma giants pay millions to Russian distributor entangled in corruption allegations to win cancer drug business - ICIJ
icij.org/investigations/cancer-calculus/pharma-giants-pay-millions-to-russian-distributor-entangled-in-corruption-allegations-to-win-cancer-drug-business/
Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC: Get the latest updates on HER2-mutated NSCLC.
medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur
)
What’s Keytruda, the best-selling drug that treats 22 cancers, but is unaffordable for most?
firstpost.com/health/keytruda-cancer-drug-unaffordable-patent-14000295.html
Just Diagnosed With HER2-Mutant Non-Small Cell Lung Cancer? Here’s What To Expect
health.clevelandclinic.org/what-to-expect-her2-nsclc

Local consolidation therapy improves results of TKI therapy in EGFR-mutated NSCLC - | German Medical Journal
aerzteblatt.de/news/lokale-konsolidierungstherapie-verbessert-ergebnisse-der-tki-therapie-beim-egfr-mutierten-nsclc-140649b8-fb72-421e-9b27-24d8ed0c662d

Good results for antibody-toxin conjugate in refractory EGFR-mutated NSCLC – Deutsches Ärzteblatt
aerzteblatt.de/news/gute-ergebnisse-fur-antikorper-toxin-konjugat-beim-refraktaren-egfr-mutierten-nsclc-6da097b5-e15e-42a6-82a7-1c542f1080af

HER2-mutated NSCLC: New tyrosine kinase inhibitors with promising efficacy – Deutsches Ärzteblatt
aerzteblatt.de/news/her2-mutiertes-nsclc-neue-tyrosinkinase-inhibitoren-mit-vielversprechender-wirksamkeit-5b11d7fb-9745-4320-9a49-f855c962f51d

Uncovering new therapeutic targets for a common KRAS mutation behind cancer: A team of Northwestern investigators has discovered novel molecular underpinnings of ...
medicalxpress.com/news/2025-10-uncovering-therapeutic-common-kras-mutation.html

WHO updates list of essential medicines to include key cancer, diabetes treatments
jamaicaobserver.com/2025/09/08/updates-list-essential-medicines-include-key-cancer-diabetes-treatments/

US approves AstraZeneca, Daiichi's treatment for lung cancer: Pharma Breakthrough: AstraZeneca and Daiichi's Datroway gets US FDA approval for advanced ...
deccanherald.com/world/us-approves-astrazeneca-daiichis-treatment-for-lung-cancer-3600115

AstraZeneca gets CDSCO nod for lung cancer drug: Pharma Breakthrough Oncology India: CDSCO approves AstraZeneca’s Osimertinib for locally advanced ...
deccanherald.com/health/astrazeneca-gets-cdsco-nod-for-lung-cancer-drug-3562420
Next